Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction

被引:33
作者
Saigo, M
Abe, S
Ogawa, M
Yamashita, T
Biro, S
Minagoe, S
Maruyama, I
Tei, C
机构
[1] Kagoshima Univ, Fac Med, Dept Internal Med 1, Kagoshima 8908520, Japan
[2] Kagoshima Univ, Fac Med, Dept Lab Mol Med, Kagoshima 8908520, Japan
关键词
myocardial infarction; age; risk factors; coagulation; fibrinolysis;
D O I
10.1055/s-0037-1616051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the association between haemostatic parameters and increased risk of myocardial infarction (MI) at a young age, we measured fibrinogen, factor VII, antithrombin III, protein C, protein S, tissue factor (TF) free form tissue factor pathway inhibitor (TFPI), plasminogen, alpha (2)-antiplasmin, tissue plasminogen activator (tPA), plasminogen activator inhibitor-I (PAI-I), and lipoprotein (a) in 140 young men with MI before age 45 and 150 age-matched healthy men. TF, TF/TFPI ratio, PAI-I, PAI-I/tPA ratio, plasminogen, and lipoprotein (a) in young MI patients were all significantly higher than controls, while TFPI, antithrombin III, and tPA were significantly lower (P <0.001 of each). Significant determinants of MI risk were PAI-I/tPA ratio (R-2 = 0.300, P <0.001), TF/TFPI ratio (R-2 = 0.049, P <0.001), antithrombin III (R-2 = 0.034, P <0.001), hyperlipidaemia (R-2= 0,019, P = 0.004), diabetes (R-2 = 0.014, P = 0.015), lipoprotein (a) (R-2 = 0.012, P = 0.023), alpha (2)-antiplasmin (R-2 = 0.014, P = 0.012), and protein C (R-2 = 0.012, P = 0.018). We conclude that the imbalances of PAI-I/tPA and TF/TFPI are significantly associated with MI at a young age, perhaps mediated via impaired fibrinolytic activity.
引用
收藏
页码:1197 / 1203
页数:7
相关论文
共 56 条
[1]   AN ANTITISSUE FACTOR PATHWAY INHIBITOR (TFPI) MONOCLONAL-ANTIBODY RECOGNIZED THE 3RD KUNITZ DOMAIN (K3) OF FREE-FORM TFPI BUT NOT LIPOPROTEIN-ASSOCIATED FORMS IN PLASMA [J].
ABUMIYA, T ;
ENJYOJI, K ;
KOKAWA, T ;
KAMIKUBO, Y ;
KATO, H .
JOURNAL OF BIOCHEMISTRY, 1995, 118 (01) :178-182
[2]  
ABUMIYA T, 1995, THROMB HAEMOSTASIS, V74, P1050
[3]   Tissue-factor antigen and activity in human coronary atherosclerotic plaques [J].
Ardissino, D ;
Merlini, PA ;
Ariens, R ;
Coppola, R ;
Bramucci, E ;
Mannucci, PM .
LANCET, 1997, 349 (9054) :769-771
[4]  
BARA L, 1994, THROMB HAEMOSTASIS, V71, P434
[5]  
BARBASH GI, 1995, EUR HEART J, V16, P313
[6]   Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function [J].
Bavenholm, P ;
de Faire, U ;
Landou, C ;
Efendic, S ;
Nilsson, J ;
Wiman, B ;
Hamsten, A .
EUROPEAN HEART JOURNAL, 1998, 19 (03) :402-410
[7]   Anticardiolipin antibodies and recurrent coronary events - A prospective study of 1150 patients [J].
Bili, A ;
Moss, AJ ;
Francis, CW ;
Zareba, W ;
Watelet, LFM ;
Sanz, I .
CIRCULATION, 2000, 102 (11) :1258-1263
[8]   Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger - A prospective study [J].
Bostom, AG ;
Cupples, LA ;
Jenner, JL ;
Ordovas, JM ;
Seman, LJ ;
Wilson, PWF ;
Schaefer, EJ ;
Castelli, WP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07) :544-548
[9]   Recurring myocardial infarction in a 35 year old woman [J].
Bux-Gewehr, I ;
Nacke, A ;
Feurle, GE .
HEART, 1999, 81 (03) :316-317
[10]   Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy [J].
Cesari, M ;
Rossi, GP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (06) :1378-1386